These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
79 related articles for article (PubMed ID: 32381910)
1. [Ⅲ.MASTER KEY Project-A Platform Study for Rare Cancers]. Okuma HS; Yonemori K Gan To Kagaku Ryoho; 2020 Mar; 47(3):436-440. PubMed ID: 32381910 [No Abstract] [Full Text] [Related]
2. Have We Found the Key to Unravel Treatment Development Lags for Rare Cancers?: MASTER KEY Project. Okuma HS; Fujiwara Y Clin Pharmacol Ther; 2019 Sep; 106(3):491-492. PubMed ID: 31121054 [No Abstract] [Full Text] [Related]
3. Response to "Have We Found the Key to Unravel Treatment Development Lags for Rare Cancers?: MASTER KEY Project". Yamashita K; Kaneko M; Narukawa M Clin Pharmacol Ther; 2019 Sep; 106(3):493. PubMed ID: 31121053 [No Abstract] [Full Text] [Related]
4. Italian cancer figures--Report 2015: The burden of rare cancers in Italy. ; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748 [TBL] [Abstract][Full Text] [Related]
5. Rare cancers in The Netherlands: a population-based study. van der Zwan JM; van Dijk BAC; Visser O; van Krieken HJHJM; Capocaccia R; Siesling S Eur J Cancer Prev; 2018 Jul; 27(4):384-390. PubMed ID: 25969132 [TBL] [Abstract][Full Text] [Related]
6. Accelerating Pediatric Cancer Drug Development: Challenges and Opportunities for Pediatric Master Protocols. Khan T; Stewart M; Blackman S; Rousseau R; Donoghue M; Cohen K; Seibel N; Fleury M; Benettaib B; Malik R; Vassal G; Reaman G Ther Innov Regul Sci; 2019 Mar; 53(2):270-278. PubMed ID: 29759018 [TBL] [Abstract][Full Text] [Related]
7. [Health system research in the Republic of Croatia 1990-2010]. Kovacević J; Sogorić S; Dzakula A Acta Med Croatica; 2010 Dec; 64(5):341-8. PubMed ID: 21692257 [TBL] [Abstract][Full Text] [Related]
8. Rare cancers: Challenges & issues. Pillai RK; Jayasree K Indian J Med Res; 2017 Jan; 145(1):17-27. PubMed ID: 28574010 [TBL] [Abstract][Full Text] [Related]
9. Data quality in rare cancers registration: the report of the RARECARE data quality study. Trama A; Marcos-Gragera R; Sánchez Pérez MJ; van der Zwan JM; Ardanaz E; Bouchardy C; Melchor JM; Martinez C; Capocaccia R; Vicentini M; Siesling S; Gatta G; Tumori; 2017 Jan; 103(1):22-32. PubMed ID: 27716878 [TBL] [Abstract][Full Text] [Related]
10. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study. Gatta G; Capocaccia R; Botta L; Mallone S; De Angelis R; Ardanaz E; Comber H; Dimitrova N; Leinonen MK; Siesling S; van der Zwan JM; Van Eycken L; Visser O; Žakelj MP; Anderson LA; Bella F; Kaire I; Otter R; Stiller CA; Trama A; Lancet Oncol; 2017 Aug; 18(8):1022-1039. PubMed ID: 28687376 [TBL] [Abstract][Full Text] [Related]
11. Rare tumors: A comprehensive analysis of cancer. Bondei Irina T; Ofelia S; Todor N; Viorica Magdalena N J BUON; 2019; 24(5):2173-2179. PubMed ID: 31786892 [TBL] [Abstract][Full Text] [Related]
12. Bayesian estimates of the incidence of rare cancers in Europe. Botta L; Capocaccia R; Trama A; Herrmann C; Salmerón D; De Angelis R; Mallone S; Bidoli E; Marcos-Gragera R; Dudek-Godeau D; Gatta G; Cleries R; Cancer Epidemiol; 2018 Jun; 54():95-100. PubMed ID: 29684802 [TBL] [Abstract][Full Text] [Related]
13. Changing the p53 master regulatory network: ELEMENTary, my dear Mr Watson. Menendez D; Inga A; Jordan JJ; Resnick MA Oncogene; 2007 Apr; 26(15):2191-201. PubMed ID: 17401428 [TBL] [Abstract][Full Text] [Related]
14. GerOSS (German Obstetric Surveillance System). A Project to Improve the Treatment of Obstetric Rare Diseases and Complications Using a Web Based Documentation and Information Platform. Berlage S; Grüßner S; Lack N; Franz HB Methods Inf Med; 2015; 54(5):406-11. PubMed ID: 26065375 [TBL] [Abstract][Full Text] [Related]
15. Real-time Leishmania genus master mix: a platform compatibility and stability study. Melanson VR; Scheirer JL; Kalina WV; Wagar EJ Diagn Microbiol Infect Dis; 2014 Oct; 80(2):97-101. PubMed ID: 25112901 [TBL] [Abstract][Full Text] [Related]
16. Papillary Thyroid Carcinoma in Pediatric Age: An Example of a Rare Tumour Managed Within a Cooperative Comprehensive Project. Sironi G; Ferrari A; Podda M; Chiaravalli S; Bisogno G; Cecchetto G; Massimino M Curr Pediatr Rev; 2016; 12(4):265-271. PubMed ID: 27804856 [TBL] [Abstract][Full Text] [Related]
17. Incidence of rare cancers in the city of São Paulo, Brazil. Bustamante-Teixeira MT; Latorre MDRDO; Guerra MR; Tanaka LF; Botta L; Trama A; Gatta G Tumori; 2019 Feb; 105(1):22-30. PubMed ID: 30700226 [TBL] [Abstract][Full Text] [Related]
18. Master protocols in clinical trials: a universal Swiss Army knife? Sudhop T; Brun NC; Riedel C; Rosso A; Broich K; Senderovitz T Lancet Oncol; 2019 Jun; 20(6):e336-e342. PubMed ID: 31162107 [TBL] [Abstract][Full Text] [Related]
19. A Simple "Boxed Molecular Kinetics" Approach To Accelerate Rare Events in the Stochastic Kinetic Master Equation. Shannon R; Glowacki DR J Phys Chem A; 2018 Feb; 122(6):1531-1541. PubMed ID: 29327936 [TBL] [Abstract][Full Text] [Related]
20. Definitions and statistical properties of master protocols for personalized medicine in oncology. Renfro LA; Mandrekar SJ J Biopharm Stat; 2018; 28(2):217-228. PubMed ID: 28877008 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]